Superworth

IQVIA price to free cash flow IQV

Market value divided by free cash flow over the last twelve months, since 2014.

Today, Oct 23, 2026
21.1×
10-year median
25.9×
Against its 10-year history
25th
percentile: 0 is its lowest day, 100 its highest
10-year range
11.0× to 47.7×
Peer median
33.5×

IQVIA's price to free cash flow is 21.1× as of Oct 23, 2026.

That is below its ten-year median of 25.9×, lower than on 75% of days in the last ten years.

Over that time it ranged from 11.0× in May 2025 to 47.7× in Feb 2020.

The median for 10 diagnostics and research stocks of a similar size is 33.5×.

Price to free cash flow over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far21.1×12.9×21.1×
202517.5×11.0×19.3×
202418.5×17.8×31.1×
202332.0×20.8×32.0×
202222.3×17.7×27.1×
202122.8×19.9×33.1×
202028.3×21.1×47.7×
201944.9×33.1×47.2×
201835.6×24.4×39.1×
201724.9×24.9×37.7×
201636.0×13.4×38.2×
201519.0×17.7×31.6×
201424.3×18.5×24.3×

Against its peers

Companies in Medical - Diagnostics & Research nearest IQVIA's size, closest first, today.

CompanyPrice to free cash flow
IQVIQVIA21.1×
WATWaters112×
IDXXIDEXX Laboratories35.2×
AAgilent Technologies38.5×
ILMNIllumina43.7×
MTDMettler-Toledo International38.7×
DGXQuest Diagnostics19.8×
LHLabcorp23.1×
MEDPMedpace26.4×
RVTYRevvity31.7×
DHRDanaher29.6×
Peer median33.5×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on IQVIA

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.